A phase II study of humanized anti-HER2 monoclonal antibody (rhuMAB HER2) and weekly chemotherapy in women with metastatic progressive breast cancer

被引：0
|
作者：
Colozz, M
Gori, S
Mosconi, AM
Di Stefano, A
Mazzoni, F
Maestri, A
Cherubini, R
Crino, L
Tonato, M
机构：
[1] Monteluce Policlin, UO Oncol Med, Perugia, Italy
[2] Osped Bellaria, UO Oncol Med, Bologna, Italy
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E20
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [21] A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel
    Kunitomo, K
    Inoue, S
    Ichihara, F
    Kono, K
    Fujii, H
    Matsumoto, Y
    Ooi, A
    HUMAN PATHOLOGY, 2004, 35 (03) : 379 - 381
  • [22] Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
    Guarneri, V.
    Barbieri, E.
    Dieci, M. V.
    Piacentini, F.
    Conte, P.
    CANCER TREATMENT REVIEWS, 2010, 36 : S62 - S66
  • [23] Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
    Malwina Stanowicka-Grada
    Elżbieta Senkus
    Current Treatment Options in Oncology, 2023, 24 : 1633 - 1650
  • [24] Advances in anti-HER2 therapy in metastatic breast cancer
    Yao, Minya
    Fu, Peifen
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [25] Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody
    Yu, Xiaojie
    Wang, Lingfei
    Shen, Yafeng
    Wang, Chao
    Zhang, Yajun
    Meng, Yanchun
    Yang, Yang
    Liang, Beibei
    Zhou, Bo
    Wang, Huajing
    Wei, Huafeng
    Lei, Changhai
    Hu, Shi
    Li, Bohua
    MOLECULAR IMMUNOLOGY, 2017, 87 : 300 - 307
  • [26] Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Stiller, Tracey
    Blanchard, M. Suzette
    Padam, Simran
    Katheria, Vani
    Kim, Heeyoung
    Sun, Canlan
    Tang, Aileen
    Martinez, Norma
    Patel, Niki Dipesh
    Sedrak, Mina S.
    Waisman, James
    Li, Daneng
    Sanani, Shamel
    Presant, Cary A.
    Mortimer, Joanne
    JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (05) : 752 - 758
  • [27] HER2 testing and its predictive utility in anti-HER2 breast cancer therapy
    Advani, Pooja P.
    Crozier, Jennifer A.
    Perez, Edith A.
    BIOMARKERS IN MEDICINE, 2015, 9 (01) : 35 - 49
  • [28] Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
    Bookman, MA
    Darcy, KM
    Clarke-Pearson, D
    Boothby, RA
    Horowitz, IR
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) : 283 - 290
  • [29] Efficacy and safety of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive or HER2-low expressing, metastatic breast cancer: a single-arm phase II study
    Qu, Fei
    Li, Wei
    Yin, Yongmei
    Liu, Qian
    CANCER RESEARCH, 2024, 84 (09)
  • [30] Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin)
    Büchler, P
    Reber, HA
    Büchler, MC
    Roth, MA
    Büchler, MW
    Friess, H
    Isacoff, WH
    Hines, OJ
    JOURNAL OF GASTROINTESTINAL SURGERY, 2001, 5 (02) : 139 - 146
12345